Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:ABCNOTCMKTS:ATTBFOTCMKTS:MEOBF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCNVIVO CannabisC$1.32+5.6%C$1.32C$0.80▼C$4.06C$256.62MN/A1.51 million shs310,601 shsATTBFAbattis Bioceuticals$0.00$0.00▼$0.00N/AN/A11,650 shsN/AMEOBFMesoblast$0.19$0.18$0.10▼$1.00N/AN/A37,980 shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCNVIVO Cannabis0.00%0.00%0.00%0.00%0.00%ATTBFAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%MEOBFMesoblast0.00%0.00%0.00%+14.04%-74.27%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCNVIVO CannabisN/AN/AN/AN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMEOBFMesoblastN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCNVIVO CannabisN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AMEOBFMesoblastN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCNVIVO CannabisN/AN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AN/AMEOBFMesoblastN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCNVIVO CannabisN/AN/A0.00∞N/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/A-$0.16N/AN/AN/AN/AN/AN/AN/AMEOBFMesoblastN/A-$0.25N/A∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCNVIVO CannabisN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AMEOBFMesoblastN/AN/AN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCNVIVO CannabisN/AATTBFAbattis Bioceuticals32.45%MEOBFMesoblast27.35%Insider OwnershipCompanyInsider OwnershipABCNVIVO CannabisN/AATTBFAbattis BioceuticalsN/AMEOBFMesoblastN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABCNVIVO CannabisN/A194.41 millionN/ANot OptionableATTBFAbattis BioceuticalsN/AN/AN/ANot OptionableMEOBFMesoblast83N/AN/ANot OptionableMEOBF, ATTBF, ABCN, ABZA, and AHZ HeadlinesSourceHeadlineMesoblast Limited (ASX: MSB) - Share Price and Researchintelligentinvestor.com.au - March 20 at 4:45 PMWhy Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com - March 11 at 2:01 PMJefferies Keeps Their Buy Rating on Mesoblast Limited (MEOBF)markets.businessinsider.com - December 26 at 11:51 PMAnalysts Are Bullish on These Healthcare Stocks: Guangzhou Baiyunshan Pharmaceutical Holdings Company (GZPHF), Mesoblast Limited (MEOBF)markets.businessinsider.com - December 25 at 12:12 AMMesoblast Ltd ADR MESOmorningstar.com - December 9 at 7:42 PMMesoblast Limited (MEOBF) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - January 11 at 6:24 PMMESO.O - Mesoblast limited (ADR) | Stock Price & Latest News | Reutersreuters.com - September 29 at 9:39 PMMesoblast Teva Startsinvesting.com - September 29 at 4:34 PMMesoblast Limited (MESO) Q4 2022 Earnings Call Transcriptseekingalpha.com - September 1 at 11:18 PMMesoblast Limited 2022 Q4 - Results - Earnings Call Presentationseekingalpha.com - September 1 at 11:18 PMMindMed Appoints Schond L. Greenway As CFOmarkets.businessinsider.com - May 25 at 9:37 AMMesoblast (OTC:MEOBF), Short Interest Reportbenzinga.com - May 25 at 9:37 AMMesoblast (OTC:MEOBF), Earnings Estimates, EPS, and Revenuebenzinga.com - May 25 at 9:37 AMMesoblast reports FQ3 resultsseekingalpha.com - April 29 at 7:22 AMMesoblast Limited (MESO) Q1 2022 Earnings Call Transcriptfool.com - March 28 at 10:10 PMWhy Mesoblast Stock Is Plunging After Q4 Earnings Report?markets.businessinsider.com - August 31 at 12:26 PMLoss-Making Mesoblast Limited (ASX:MSB) Expected To Breakeven In The Medium-Termfinance.yahoo.com - August 24 at 10:19 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsVIVO CannabisCVE:ABCNABcann Global Corporation manufactures and distributes medical cannabis. The company is headquartered in Napanee, Canada.Abattis BioceuticalsOTCMKTS:ATTBFAbattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.MesoblastOTCMKTS:MEOBFMesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.